Rhythm Pharmaceuticals, Inc. (RYTM)
After hours:
| Previous close | 43.88 |
| Open | 39.60 |
| Bid | 39.31 x 100 |
| Ask | 39.45 x 200 |
| Day's range | 37.49 - 41.76 |
| 52-week range | 15.50 - 52.57 |
| Volume | |
| Avg. volume | 578,831 |
| Market cap | 2.399B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial evaluating setmelanotide in hypothalamic obesity remains on track for topline data readout in 1H 2025; dosing of first patients in Japan anticipated in 2Q 2024 -- -- Secured $150 million in convertible preferred stock financ
- GlobeNewswire
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- Company remains on track to complete submission of sNDA to the FDA seeking a label expansion for pediatric patients in 1H 2024 -- -- Two additional posters presented at PES 2024 -- BOSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, In
- GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendo
